Navigation Links
Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Date:11/1/2007

tform product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone- refractory prostate cancer, as well as a Phase 1 clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, and the efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as amended, and most cu
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 2011 Hill-Rom Holdings, Inc. (NYSE: HRC ) ... January 26, 2011.  The company will host a webcast the ... EST. Earnings Release:   Hill-Rom,s Fiscal 2011 ... 2010, will be issued to the public after the close ...
... Amarin Corporation plc (Nasdaq: AMRN ) (the "Company"), ... today announced that it has completed its previously announced underwritten ... to the public of $7.60 per ADS. Due ... the company sold a total of 13,800,000 ADSs in the ...
Cached Medicine Technology:Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast 2Amarin Announces Successful Completion of Offering of American Depositary Shares 2Amarin Announces Successful Completion of Offering of American Depositary Shares 3
(Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... reputation for being highly toxic, but when used in the ... to offer potential health benefits in a range of issues, ... compound (AP39), designed and made at the University of Exeter, ... of very small amounts of the substance to the right ... have already found that the compound protects mitochondria the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... a way to predict whether women with ductal carcinoma in ... cancer are at risk of developing more invasive tumors ... women with DCIS will have the opportunity to be more ... will have much more information, so they can better know ...
... for Radiation Oncology (ASTRO) has released its Emerging ... body radiotherapy (SBRT) in lung cancer treatment. SBRT ... focused radiation beams to target a well-defined tumor ... planning and precise treatment setup to deliver the ...
... release is available in French . , Ottawa, ... ideas amongst researchers is a fundamental element in turning knowledge ... Thanks to the newly launched PubMed Central Canada (PMC Canada), ... archive of published Canadian health research. PMC Canada ...
... researchers find , WEDNESDAY, April 28 (HealthDay News) -- ... lung disease caused by cystic fibrosis: Which comes first, ... beginning to answer that question, and it looks like ... an assistant professor of internal medicine at the University ...
... ... Air” in HuffPost Living , ... (PRWEB) April 28, 2010 -- Huffington Post blogger and radio host Kathleen ... radio program, The Kathleen Show ., , ,Each week in The Huffington Post ...
... ... , ... 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and ... care programs in connection with its marketing and promotional practices for the blockbuster atypical ...
Cached Medicine News:Health News:Breakthrough method predicts risk of invasive breast cancer 2Health News:Breakthrough method predicts risk of invasive breast cancer 3Health News:Canada joins international network providing free access to health research 2Health News:Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease 2Health News:The Kathleen Show Launches Weekly Audio Blog on The Huffington Post 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 3
Microscissors : Horizontal Scissors...
Disposable Microscissors: Vertical, 90...
Microscissors: Eckardt Vertical Retinomy Scissors...
... the original and very popular ... for cutting in the vertical ... curved tips allow greater versatility ... retlna. Tip is shaped like ...
Medicine Products: